# Allergy Therapeutics Progressive development across portfolio

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-progressive-development-across-portfolio/412726723
- Published: 2017-04-05T07:43:52+01:00
- Author: Giles Arbor

**[⌊Hardman & Co Report Report Downloads⌉⌊Hardman & Co Report Report Downloads⌉[Allergy Therapeutics Plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)) is a long-
established specialist in the prevention, diagnosis and treatment of allergies. 
Pollinex Quattro continues to gain market share despite being available in EU only
on a ‘Named Patient’ basis. Trials to obtain full approval as a biological have 
progressed well in EU with the first patient recruited in the pivotal birch pollen
allergy vaccine Phase III trial. US trials are back on-track with a new safety trial
underway. A Phase I study of Acarovac MPL, a ‘dust mite allergy’ vaccine, has been
approved in Spain for 32 patients. Finally, Polyvac Peanut has completed pre-clinical
testing and has potential to significantly disrupt the peanut allergy market.

 

**Sales:** Underlying sales were strong during H1’17, with +18% CER growth to £34.2m.
Sales were greatly strengthened on translation to £40.4m since >94% of the company’s
sales are generated in mainland Europe. In Europe, AGY’s market share has reached
13%, whilst its global market share is up to 8.2%.

**Clinical development:** AGY announced three significant updates to its clinical-
stage therapies this period. Notable was the first recruitment to the Phase III 
trial of the birch allergy therapy in EU, the first Pollinex Quattro candidate to
enter Phase III, and also CTA approval of the first clinical trial of Acarovac.

**R&D:** AGY continues to invest in pre-clinical research alongside its clinical
stage portfolio. Research is underway to explore the application of proprietary 
adjuvant technologies to infectious disease vaccines, including malaria. For Polyvac
Peanut, positive efficacy and safety data were reported in a proof-of-concept study.

**Forecasts:** Our forecasts for the full year have not changed; they were last 
altered following the Jan’17 trading update. Total R&D investment is forecast to
accelerate in 2H’17 and rise further when the larger US trials get underway in fiscal
2018. The ongoing EU trials are less expensive relative to US trials.

**Investment summary:** It is an exciting time for Allergy Therapeutics Plc, which
is gaining market share for its Pollinex franchise in Europe and which is investing
heavily in clinical development to achieve full Pollinex Quattro EU registration.
The planned route into the US is back on track following FDA discussions. Read out
from the EU Phase III PQBirch trial in 2018 will provide the next major value inflection
point.

Share on:
